This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Dr. Farhan Bhatti, a family physician and Michigan State lead for the Committee to Protect Health Care, joined Cheddar to discuss the newly discovered and highly transmissible omicron variant of COVID-19. Bhatti said it is too early to draw any conclusions about the new variant but there is concern that it could eventually mutate and develop a resistance to vaccines. "Time will tell, but for now, it looks like, still, the best thing that we can do to try to limit the spread of this disease is make sure everybody gets a vaccine and make sure everybody avoids large gatherings indoors and wears masks during the wintertime especially," he said.
Jill and Carlo cover the latest developments with the Omicron variant that are spooking markets once again. Twitter's @Jack is leaving, SCOTUS takes up abortion rights and the world has a brand new republic.
A CDC panel unanimously endorsed Moderna and Pfizer Covid-19 vaccine boosters for all U.S. adults. This comes after the FDA gave its own authorization for everyone 18 and older, scrapping previous eligibility factors like age and underlying conditions. Dr. Shereef Elnahal, President and CEO of University Hospital and former New Jersey Health Commissioner, joined Cheddar News to break down the development.
The Biden Administration is set to buy 10 million courses of Pfizer's Covid pill if it gains emergency use authorization from the FDA. With this purchase, the U.S. will receive more than 13 million courses of antiviral pills aimed at treating Covid and reducing severe illness and death. Pfizer's pill has been shown to reduce risk of hospitalization and death by 89 percent, proving it could be a key tool in the fight against the pandemic. Dr. Soumi Eachempati, Co-Founder, CEO & CMO of Cleared4, joined Cheddar News to discuss.
Dr. David Dodson, Infectious Disease Specialist at Carden & Dodson MD, joined Wake Up With Cheddar to break down what we know so far about the Omicron Covid-19 variant, and why you shouldn't wait for an Omicron-specific shot to get vaccinated.
Friday saw big sell offs, with the Dow Jones posting its worst day since October 2020, falling 905 points, with the Nasdaq and S&P 500 each tumbling more than two percent as well. Much of that due to investor concerns over the new Covid-19 'Omicron' variant first detected in South Africa. Craig Erlam, senior market analyst at Oanda explains what investors should expect this week.
The ocean is an important topic when it comes to the climate. It plays a vital role in shaping our environment, with rising sea levels causing a 35% increase in natural disasters around the world, affecting 1.7 billion people. Dr. Sylvia Earle has been called perhaps the greatest advocate our oceans have ever had, with Time magazine dubbing her its first 'hero of the planet' and the Library of Congress naming her a living legend. She is also the founder of Mission Blue, an organization that inspires action to explore and protect the ocean. Dr. Earle joined Cheddar Climate for more on the importance of caring for the ocean and its impact on climate change.
Scientists are racing to understand the Omicron variant of covid-19 and find out just how dangerous it really is. Omicron, dubbed a variant of concern by the WHO, was first detected in South Africa last week and has already spread to multiple countries, including the UK, Canada, Australia and more. Dr. Jonathan Javitt, CEO of Nrx and adjunct professor at Johns Hopkins School of Medicine, joined Cheddar to discuss what we know and don't know about this new variant.
The House has officially passed the $1.75 trillion social policy and climate big. This new bill is expected to bring some huge investments into working towards fighting climate change. U.S. President of We Don't Have Time, Sweta Chakraborty, joined Cheddar to discuss more.
